Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, explains the results of a phase 1 trial using combination magrolimab and azacitidine for older patients with acute myeloid leukemia (AML). Compared to the standard of care using azacitidine and venetoclax, the phase 1 trial shows higher complete response rates and overall response rates for the magrolimab plus azacitidine cohort. Click here to learn more.